Matthew Boron, R.Ph.

Mr. Boron joined the Cancer Therapy Evaluation Program (CTEP) in 2000 as a Clinical Research Pharmacist. In this role, he was responsible for a portfolio of biologic agents under CTEP Investigational New Drug applications (INDs).  In 2002, he transitioned to management of the Treatment Referral Center (TRC), which provides referrals to clinical trials and mechanisms for access to NCI IND agents when conventional therapy and clinical trial therapies are no longer an option. In addition to the TRC, he is also responsible for management of a portfolio of IND agents and acts as lead pharmacist for blinded trials conducted through CTEP. He also serves as a Contract Officer Representative (COR).  He took on additional responsibilities as Associate Branch Chief.

 Mr. Boron earned his bachelor of science degree in pharmacy from Duquesne University.  Prior to his work at the NCI, he practiced at several large academic intuitions in their inpatient and outpatient oncology services.  He has also spent time working for a large pharmaceutical company handling drug information questions.